Trials / Completed
CompletedNCT03174366
Investigating the Use of Prolia (Denosumab) in the Treatment of Acute Charcot Neuroarthropathy
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 7 (actual)
- Sponsor
- Western University of Health Sciences · Academic / Other
- Sex
- Male
- Age
- 30 Years
- Healthy volunteers
- Not accepted
Summary
Charcot neuroarthropathy (CN) is a debilitating disease primarily affecting poorly controlled diabetic patients with peripheral neuropathy. The consequences of CN include ulcerations of the foot and ankle, osteomyelitis, and severe musculoskeletal deformity. These consequences frequently lead to below-knee amputation of the affected limb. Currently treatment options are limited, and no pharmaceutical treatment has been efficacious in the medical literature. The purpose of this pilot study is to investigate the potential of the medication denosumab for acute stage Charcot neuroarthropathy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Denosumab | Subjects will receive medication once following enrollment, and will be monitored for 1 year thereafter. |
Timeline
- Start date
- 2017-05-16
- Primary completion
- 2018-06-18
- Completion
- 2019-03-06
- First posted
- 2017-06-02
- Last updated
- 2019-10-23
- Results posted
- 2019-10-23
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03174366. Inclusion in this directory is not an endorsement.